Journal
PLOS ONE
Volume 10, Issue 5, Pages -Publisher
PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0128636
Keywords
-
Categories
Funding
- [U54 AI057160]
- [R01 CA043059]
- [U19 AI083019]
- [U19 AI106772]
- [R01 AI104972]
Ask authors/readers for more resources
Although type I interferons (IFNs) were first described almost 60 years ago, the ability to monitor and modulate the functional activities of the individual IFN subtypes that comprise this family has been hindered by a lack of reagents. The major type I IFNs, IFN-beta and the multiple subtypes of IFN-alpha, are expressed widely and induce their effects on cells by interacting with a shared heterodimeric receptor (IFNAR). In the mouse, the physiologic actions of IFN-alpha and IFN-beta have been defined using polyclonal anti-type I IFN sera, by targeting IFNAR using monoclonal antibodies or knockout mice, or using Ifnb(-/-) mice. However, the corresponding analysis of IFN-alpha has been difficult because of its polygenic nature. Herein, we describe two monoclonal antibodies (mAbs) that differentially neutralize murine IFN-beta or multiple subtypes of murine IFN-alpha. Using these mAbs, we distinguish specific contributions of IFN-beta versus IFN-alpha in restricting viral pathogenesis and identify IFN-alpha as the key mediator of the antiviral response in mice infected with West Nile virus. This study thus suggests the utility of these new reagents in dissecting the antiviral and immunomodulatory roles of IFN-beta versus IFN-alpha in murine models of infection, immunity, and autoimmunity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available